株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品の取引動向

Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics

発行 GlobalData 商品コード 531729
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
医薬品の取引動向 Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics
出版日: 2017年07月01日 ページ情報: 英文
概要

当レポートでは、医薬品・ヘルスケア市場における取引決定の重要性について検証し、取引活動の促進要因、主な戦略、最近の取引活動などを含めて、体系的な情報を提供しています。

イントロダクション

  • 概要
  • 取引活動を促進する要因
  • 取引で実行される主な戦略
    • 地理的拡大
    • ポートフォリオの強化
    • 市場の統合
    • 研究開発の向上
    • 製品ライフサイクル管理
    • 希少疾患市場への参入

取引タイプ

  • M&A
    • 概要
    • 発表された主な取引
    • 終了
  • 資産交換
    • 主な資産交換
  • パートナーシップ
    • 概要
    • 発表された主な取引
    • 終了
  • ライセンス
    • 概要
    • 発表された主な取引
    • 終了

医薬品取引の概要

  • 医薬品取引:金額・年別
  • 取引件数:地域/国別
  • 取引件数:有望な治療分野別
  • 取引件数:開発段階別
  • 取引件数:分子タイプ別
  • 取引件数と金額:取引タイプ別

主要企業

結論と将来の見通し

参考文献

目次
Product Code: GBI081CBR

Although the pharmaceutical market is continuing to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome these challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.

Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence. Additionally, many companies have successfully implemented deal-making strategies to secure extended protection for their products from generic competitors. Deal activity can help pharma companies to enhance their research and regulatory approaches, and can aid portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.

This report analyzes the importance of deal making in the pharmaceutical and healthcare market. It covers key factors that encourage deal activity in the pharmaceutical industry, and the key strategies being implemented when companies strike deals. An overview of recent deal activity from 2010 to May 2017 is also included.

Scope:

  • What deal making strategies have been used in recent years to boost R&D productivity and allow the successful commercialization of pharmaceutical products?
  • In which geographical markets and disease areas has deal activity been focused since 2010?
  • At which stage of development did deals most frequently occur, and attract the highest value?
  • How have pharma companies been using deal making to strengthen their product portfolio and bottom line?
  • What are the most significant Mergers and Acquisitions (M&As), licensing deals and partnership deals to have been announced since 2016?
  • Who are the major players in pharmaceutical deal making, and what has been their recent and key deal activity?

Reasons To Buy:

  • Gain a comprehensive understanding of the most recent healthcare deal trends.
  • Understand the most significant M&As, licensing deals and partnerships to have occurred in recent years.
  • Comprehensively analyze the trends of deal activity from 2010 to May 2017, with respect to aggregate deal value, geography, and the therapy area and stage of development of the products involved.
  • Understand the deal-making strategies that have been historically implemented by companies, and identify the most suitable strategies for boosting R&D portfolio and bottom line performance.
  • Identify the key deal terminations that have occurred in recent years, and understand their effect.

Table of Contents

  • Introduction
  • Overview
  • Factors Promoting Deal Activity
  • Key Strategies Implemented in Deals
  • Geographical Expansion
  • Portfolio Enhancement
  • Market Consolidation
  • Improving Research and Development
  • Product Lifecycle management
  • Entry into Rare disease Markets
  • Deal Types
  • Mergers and Acquisitions (M&As)
  • Overview
  • Key Announced Deals in M&As
  • Terminated M&As
  • Asset Swaps
  • Key Asset Swaps
  • Partnerships
  • Overview
  • Key Announced Deals
  • Terminated Partnerships
  • Licensing
  • Overview
  • Key Announced Deals
  • Terminated Licensing deals
  • Overview of Pharmaceutical Deals from 2010 to 2016
  • Pharmaceutical Deals by Value and Year
  • Number of Deals by Region/Country
  • Number of Deals by Prominent Therapy Area
  • Number of Deals by Stage of Development
  • Number of Deals by Molecule Type
  • Number of deals and Value by Type of Deal
  • Key Players
  • Conclusions and Future Scope
  • Bibliography
Back to Top